Navigation Links
Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs

CARMIEL, Israel, Dec. 17 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX) today announced the appointment of Sandra Lauterbach to Vice President, Sales and Commercial Affairs. In this newly created, U.S. based position, Ms. Lauterbach will be responsible for all commercial activities, including pre-launch and launch activities for taliglucerase alfa in accordance with the collaboration agreement between the Company and Pfizer Inc., as well as any other products that emerge from the Company's pipeline. Ms. Lauterbach brings over 20 years of expertise in U.S. and global marketing, commercial strategy, and product development for pharmaceutical and biotechnology companies. Prior to joining the Company, she served as Vice President of Marketing, Endocrinology at EMD Serono and Senior Director, Global Marketing for Fabrazyme at Genzyme Corporation.

"We are delighted to have someone with Sandra's sales and commercial experience join Protalix," said Dr. David Aviezer, the Company's President and Chief Executive Officer. "Her experience and track record with pre-launch and launch activities, particularly in the rare genetic disease space, will be a tremendous asset to our company as we transition from a research and development organization to a fully integrated biotechnology company."

Ms. Lauterbach's career includes more than 20 years of sales and marketing experience in the healthcare industry. As Vice President of Marketing, Endocrinology at EMD Serono, she developed, executed, and managed the national marketing strategies for Saizen®, Gonal-f® and Serostim®. Prior to her tenure at Serono, Ms. Lauterbach spent four years at Genzyme leading the international product team for Fabrazyme, which produced double-digit annual growth for three straight years. Her background also includes several years with Immune Mediated Disease, Vertex Pharmaceuticals Incorporated, Amgen Inc. and Merck Human Health.

Ms. Lauterbach received her Bachelor of Science in Molecular Biology from the University of Wisconsin and her Masters in Business Administration from the University of South Florida.

About Protalix

Protalix is a biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins expressed through its proprietary plant cell based expression system. Protalix's ProCellEx(TM) presents a proprietary method for the expression of recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins in an environment free of mammalian components and viruses. Protalix is also advancing additional recombinant biopharmaceutical drug development programs. Taliglucerase alfa is an enzyme replacement therapy in development under a Special Protocol Assessment with the U.S. Food and Drug Administration for Gaucher disease.

Safe Harbor Statement:

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause material differences include, among others, risks relating to: the successful preclinical development of our product candidates; the completion of clinical trials; the review process of the FDA, foreign regulatory bodies and other governmental regulatory bodies, including the FDA's review of any filings we make in connection with the treatment protocol; delays in the FDA's or other health regulatory authorities' approval of any applications we file or refusals to approve such filings; refusals by such regulatory authorities to approve the marketing and sale of a drug product even after acceptance of an application we file for any such drug product; the identification of lead compounds; the risk that we may fail to satisfy certain conditions relating to grants we have received from the Office of the Chief Scientist of Israel's Ministry of Industry and Trade which may lead to our being required to refund grants previously received together with interest and penalties; the risk that the Office of the Chief Scientist may not deliver to us all of the funds awarded to us; uncertainties related to the ability to attract and retain partners for our technologies and products under development; and other factors described in our filings with the Securities and Exchange Commission. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or in preliminary findings for such clinical trials. Further, even if favorable testing data is generated by clinical trials of drug products, the FDA may not accept or approve an NDA filed by a pharmaceutical or biotechnology company for such drug product. Failure to obtain FDA approval of any of our drug candidates in a timely manner, if at all, will severely undermine our business and results of operation by reducing our potential marketable products and our ability to generate corresponding product revenues. Under our approved treatment protocol, taliglucerase alfa might be provided only to a limited number of patients and only for a limited time. The FDA's approval of the treatment protocol or the fast track designation will not have any effect on the FDA's approval of the NDA we filed with respect to taliglucerase alfa, if any, and the review by the FDA of any data from our Phase III clinical development programs in connection with the approval of the treatment protocol will not have any effect on the FDA's subsequent review of our complete Phase III clinical trial data in the future. The statements in this release are valid only as of the date hereof and we disclaim any obligation to update this information.

    Marcy Nanus
    The Trout Group, LLC
    Telephone: 646-378-2927

    Media Contact:
    Brad Miles
    BMC Communications Group, LLC
    Telephone: 212-477-9007 x17

SOURCE Protalix BioTherapeutics, Inc.

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
2. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
3. CVS Caremark Names New Chief Human Resources Officer
4. Cardinal Health Names Carrie Cox to Board of Directors
5. Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO
6. The Deal Names Abbott Top Dealmaker for Second Consecutive Year
7. IDEV Technologies Names Christopher M. Owens President, Chief Executive Officer
8. AMD LASERS Names Dr. James Jesse as Medical Director
9. Arcadia Resources Names Stephen Goldsmith to Board of Directors
10. NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations
11. Codexis Names Fernando Valle Research Fellow
Post Your Comments:
(Date:10/8/2015)... October 8, 2015 " Biomedical ... Growth, Trends and Forecast 2014 - 2022 " , ... 2.63 billion in 2013 and is anticipated to expand at ... USD 4.00 billion in 2022. --> " ... Share, Growth, Trends and Forecast 2014 - 2022 " ...
(Date:10/8/2015)... N.C. , Oct. 8, 2015  Clariant, a world ... Packaging manufacturing facility in Belen, New Mexico ... for healthcare applications, including desiccant canisters and packets ... Belen plant is the second Clariant site – ... – to meet the ISO 15378:2011 standards, following only the ...
(Date:10/8/2015)... , Oct. 8, 2015  Nektar Therapeutics (Nasdaq: ... pain and oncology portfolio during an Investor and Analyst ... p.m. Eastern Time in New York City ... of the NKTR-214 Phase 1/2 clinical program and biomarker ... cytokine designed to preferentially stimulate the production of CD8-positive ...
Breaking Medicine Technology:
... SHP ) ("ShangPharma" or the "Company"), a ... company, today announced that it will release its unaudited ... ended December 31, 2011 on March 13, 2012. Management ... at 08:00AM New York Time on March 13, 2012 ...
... 28, 2012  Based on its recent analysis of ... Brainsway with the 2012 Global Frost & Sullivan ... Magnetic Stimulation (dTMS) is the only non-invasive technique ... depression and other neuro-psychiatric disorders without causing any ...
Cached Medicine Technology:
(Date:10/9/2015)... CA (PRWEB) , ... October 09, 2015 , ... ... anniversary of their “Agents of Change” program, a community improvement initiative that involves ... newest charity to benefit from the assistance of Confidence Plus Insurance is the ...
(Date:10/9/2015)... ... October 09, 2015 , ... Prescription Hope, the fastest ... of life to save money on the high cost of their prescription medications ... medication, individuals and families can receive their medications delivered direct from over 180 ...
(Date:10/9/2015)... ... October 09, 2015 , ... Santa Rosa Consulting and ... as MD Anderson prepares to go-live on the Epic platform in March of 2016. ... 2016. Santa Rosa will execute the contract by supporting Scheduling Appointment Conversion and the ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... counseling, recently opened its newest office in Maryland – its Bethesda ... a background as a project management technology consultant to many of the largest ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... franchise, was recognized by Cabarrus County Active Living and Parks for its outstanding ... care company’s dedication to consistently going above and beyond the call of ...
Breaking Medicine News(10 mins):
... Latest version of the "All About Me" Children,s Health Journal has just ... and keep track of their childrens, immunizations and developmental progress. It is ... coast to coast have been using it since its inception. A diaper ... ...
... Health Properties, Inc. (NYSE: NHP ) announced the tax treatment for its 2008 dividend ... COMMON STOCK (CUSIP# 638620104), 2008 ... Return Total Unrecaptured, Record ... Capital Section, Date ...
... into effect, granting children 12 years and older a ... right to access condoms. But current policies allow ... out condomspolicies that two researchers, writing in this week,s ... of the country,s youth. , Juliana Han (Harvard Law ...
... lifestyle interventions that not only modify diet and physical ... obese children lose weight and maintain that loss for ... that in adolescents the effect lasts for at least ... to behaviour change programs for adolescents may provide additional ...
... PARK, Calif., Jan. 20 Exponent, Inc. (Nasdaq: ... for the fourth quarter and fiscal year ended January 2, ... February 4, 2009. The Company will host a corresponding ... 1:30 p.m. Pacific Time. Michael Gaulke, Chairman and Chief ...
... researchers say , , TUESDAY, Jan. 20 (HealthDay News) -- ... a saliva test for monitoring type 2 diabetes, which ... first time, researchers from Oregon and India have identified ... with diabetes than in non-diabetics. Using these proteins, they ...
Cached Medicine News:
Incontinence Pessaries...
Incontinence Dish - Stress Incontinence with mild prolapse. Incontinence Dish with support - Stress Incontinence with mild prolapse and mild cystocele...
The Set comes with a cross reference chart that translates ring size into the correct size of other EvaCare pessaries. The Fitting Set can be disinfected in three ways: autoclaved, boiled or cold ste...
The donut pessary is designed for third degree prolapse as well as cystocele and rectocele. The soft donut can be compressed for insertion. It is available in seven sizes....
Medicine Products: